Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Francesca Cottini, Ana Maria Avila Rodriguez, Karen Sweiss, Chukwuemeka Uzoka, Zhengjia Chen, Weiwei Ma, Elvira Umyarova, Anjali Satoskar, Pierre Rodriguez, Matias Sanchez

Blood (2024) 144 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2024-198929

Published: 2024

Journal Articles

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Lucas Maahs, Matthew Koshy, Karen Sweiss, Kang-hyun Ahn, Zhengjia Chen, Chukwuemeka Uzoka, Carlos Galvez, Paul Rubinstein, John Quigley, Santosh L. Saraf, Ana Maria Avila Rodriguez, Bulent Aydogan, Nadim Mahmud, Damiano Rondelli

Blood (2023) 142 (Supplement 1): 4897.

https://doi.org/10.1182/blood-2023-179270

Published: 2023

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 7311–7312.

https://doi.org/10.1182/blood-2022-170062

Published: 2022

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Jing C. Ye, Ravi Vij, Craig C. Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Jeffrey M. Switchenko, Sagar Lonial, Jonathan L. Kaufman

Blood (2021) 138 (Supplement 1): 2758.

https://doi.org/10.1182/blood-2021-153922

Published: 2021

Journal Articles

Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Jason T. Romancik, MD, Pamela B. Allen, MD MSc, Edmund K. Waller, PhDMD, Zhengjia Chen, PhD, Kelly Valla, PharmD, Kaylan Dixon, BS, David J. Reagan, Amanda B. Colbert, Cecilia Rosand, PA-C, Alexandra Palmer, NP-C, Christopher Flowers, MDMS, Jonathon B. Cohen, MDMS

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-141030

Published: 2020

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MDMPH, Leonard Heffner, MD, Craig E. Cole, MD, J Christine Ye, MDMSc, Ravi Vij, MBBS, Craig C Hofmeister, MDMPH, John Rushton, PhD, Zhengjia Chen, PhD, Zhao Chang, PhD, Munevver Cinar, MD, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 3188.

https://doi.org/10.1182/blood-2019-131223

Published: 2019

Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, MD, Craig E. Cole, MD, Leonard Heffner, MD, Ajay K Nooka, MDMPH, Ravi Vij, MBBS, Nyaya Kelkar, Akshata Sridhar, Munevver Cinar, MD, Zhengjia Chen, PhD, Zhao Chang, PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD

Blood (2018) 132 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2018-99-119337

Published: 2018

Journal Articles

Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 1501.

https://doi.org/10.1182/blood.V130.Suppl_1.1501.1501

Published: 2017

Journal Articles

An Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B-Cell Lymphoma Patients

Wilton Edward Robinson, Jr., MPH, Yuzi Zhang, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5220.

https://doi.org/10.1182/blood.V130.Suppl_1.5220.5220

Published: 2017

Journal Articles

Results of Interim PET/CT Imaging during Front-Line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5156.

https://doi.org/10.1182/blood.V130.Suppl_1.5156.5156

Published: 2017

Journal Articles

High-Risk FLIPI Score at Diagnosis Is Associated with Early Relapse in the Rituximab Era for Patients with Follicular Lymphoma

Max L. Goldman, BA, Chaejin Kim, PharmD, Zhengjia Chen, PhD, Oscar Calzada, BS, Michael C Churnetski, BS, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5158.

https://doi.org/10.1182/blood.V130.Suppl_1.5158.5158

Published: 2017

Journal Articles

Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma

Pooja Chandra, Olufunke Akinbobuyi, Albert Liao, Jyoti Arora, MS, Zhengjia Chen, Mary J Lechowicz, MD, Amelia A. Langston, Jeanne Kowalsky, PhD, Jonathon B. Cohen, MD, Christopher R Flowers, Leon Bernal-Mizrachi, MD

Blood (2015) 126 (23): 5043.

https://doi.org/10.1182/blood.V126.23.5043.5043

Published: 2015

Journal Articles

Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant

Chandra Pooja, MD, Ajay K. Nooka, MD MPH, Monica S. Chatwal, MD, Sungjin Kim, MS, Zhengjia Chen, PhD, Jeanne Kowalski, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Leon Bernal-Mizrachi, MD

Blood (2014) 124 (21): 3973.

https://doi.org/10.1182/blood.V124.21.3973.3973

Published: 2014

Journal Articles

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Leon Bernal-Mizrachi, MD, Ajay K Nooka, MD MPH, Chandra Pooja, MD, Monica S Chatwal, Sungjin Kim, MS, Zhengjia Chen, PhD, Jeanne Kowalski, PhD, Jonathan L. Kaufman, MD, Sagar Lonial, MD

Blood (2014) 124 (21): 2525.

https://doi.org/10.1182/blood.V124.21.2525.2525

Published: 2014

Journal Articles

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

R. Donald Harvey, PharmD, Meagan S. Barbee, PharmD, Ajay K. Nooka, MD, MPH, Sungjin Kim, MS, Zhengjia Chen, PhD, Leonard T. Heffner, MD, Jonathan L. Kaufman, MD, Sagar Lonial, M.D.

Blood (2013) 122 (21): 1958.

https://doi.org/10.1182/blood.V122.21.1958.1958

Published: 2013

Journal Articles

Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma

Sampath Ramachandiran, PhD, Xiangxue Guo, PhD, Laurent Garderet, MD, Souhila Ikhlef, MD, Jean El-cheikh, MD, Michael R Weil, PhD, Andrew N Young, M. D., Ph.D., Mahir Bagirov, Sagar Lonial, MD, Zhengjia Chen, PhD, Jeanne Kowalsky, PhD, Yuhong Du, Ph.D, Hanna J. Khoury, MD, Susan Sunay, Jonathan L. Kaufman, MD, Lawrence H. Boise, PhD, Michael Rossi, PhD, Leon Bernal-Mizrachi, MD

Blood (2011) 118 (21): 2891.

https://doi.org/10.1182/blood.V118.21.2891.2891

Published: 2011

Journal Articles

Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Disni Muringampurath-John, MBBS, Christopher R. Flowers, MD, Adnan A Jabbar, MD, PhD, Rajni Sinha, MD, MRCP, Martha Arellano, MD, Leon Bernal-Mizrachi, MD, Jonathan L. Kaufman, MD, David L. Jaye, MD, Zhengjia Chen, Mary Jo Lechowicz, MD, Sagar Lonial, MD, James O. Armitage, M.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 2947.

https://doi.org/10.1182/blood.V114.22.2947.2947

Published: 2009

Journal Articles

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Hisaki Fujii, Geoff Cuvelier, Kevin She, Soudabeh Aslanian, Hiromi Shimizu, Amina Kariminia, Mark Krailo, Zhengjia Chen, Rob McMaster, Axel Bergman, Frederick Goldman, Stephen A. Grupp, Donna A. Wall, Andrew L. Gilman, Kirk R. Schultz

Blood (2008) 111 (6): 3276–3285.

https://doi.org/10.1182/blood-2007-08-106286

Published: 2008

Journal Articles

Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).

Hisaki Fujii, MD, Kevin She, MSc, Soudabeh Aslanian, BSc, Hiromi Shimizu, BSc, Mark Krailo, PhD, Zhengjia Chen, MS, Frederick Goldman, MD, PhD, Donna A. Wall, MD, PhD, Andrew L. Gilman, MD, Kirk R. Schultz, MD

Blood (2006) 108 (11): 3232.

https://doi.org/10.1182/blood.V108.11.3232.3232

Published: 2006

Journal Articles

Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group

Smita Bhatia, Mark D. Krailo, Zhengjia Chen, Laura Burden, Frederic B. Askin, Paul S. Dickman, Holcombe E. Grier, Michael P. Link, Paul A. Meyers, Elizabeth J. Perlman, Aaron R. Rausen, Leslie L. Robison, Teresa J. Vietti, James S. Miser

Blood (2006) 109 (1): 46–51.

https://doi.org/10.1182/blood-2006-01-023101

Published: 2006

Includes: Supplemental data

NARROW

Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Addition of Myeloablative Doses of Total Marrow Irradiation (TMI) to Myeloablative Fludarabine/Busulfan Conditioning for Allogeneic HSCT in Patients with High-Risk AML, CML, or Myelodysplastic Syndrome: A Phase II Clinical Trial

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Surveillance Imaging during First-Remission in Follicular Lymphoma Does Not Impact Overall Survival

An Investigation of Potential Prognostic Factors in Late Relapse Diffuse Large B-Cell Lymphoma Patients

Results of Interim PET/CT Imaging during Front-Line Induction in Follicular Lymphoma Do Not Predict Survival Outcomes

High-Risk FLIPI Score at Diagnosis Is Associated with Early Relapse in the Rituximab Era for Patients with Follicular Lymphoma

Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma

Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients

Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma

Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Inflammatory Markers and Autoantibodies That Correlate with Early and Late Onset of New Onset Pediatric Chronic Graft-Versus-Host Disease (GVHD).

Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only